Skip to main content

Vyome Holdings, Inc

corporate_fare Company Profile

Vyome Holdings, Inc

HIND·NASDAQ·Life Sciences·CIK 0001427570

Vyome Holdings, Inc. is a clinical-stage specialty pharmaceutical company based in Cambridge, MA, Princeton, NJ, and New Delhi, India. The company focuses on treating immune-inflammatory and rare diseases with next-generation therapeutic solutions, leveraging a US-India innovation corridor. On August 15, 2025, the company completed a merger with Vyome Therapeutics, Inc., resulting in the company being renamed "Vyome Holdings, Inc." and Vyome Therapeutics, Inc. continuing as a subsidiary. Vyome Holdings, Inc.'s lead program is VT-1953, a topical gel in development to treat signs and symptoms of malignant fungating wounds in advanced cancer. This program has announced positive results from a phase 2 investigator-initiated trial. The company plans discussions with the Food & Drug Administration (FDA) on a pivotal phase 3 trial design in the first half of 2026. The company also has VT-1908, an ophthalmic drops program in the Pre-Investigational New Drug application stage. This program is a repurposed immune modulator intended to treat steroid-sparing anterior uveitis. Additionally, VB1953, a late clinical-stage program for moderate to severe acne, has completed its Phase II clinical trial and is Phase 3-ready.

Vyome Holdings, Inc (NASDAQ:HIND) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for HIND at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for HIND spans 10-Q, 8-K, PRE 14A, 10-K.

Recent high-impact activity:

  • Vyome Q3 Loss Nearly Doubles Analyst Estimates as Revenue Misses Zero Bar
  • Vyome Q3 Loss Narrows to $930K; Material Weaknesses Persist, FDA Seeks More VT-1953 Data
  • Vyome Secures USPTO Notice of Allowance for VT-1908 Ocular Inflammation Patent
  • Vyome Posts Q2 Loss, FDA Feedback on VT-1953, and JAK Inhibitor Deal
  • Vyome Q2 Loss Widens to $719K; FDA Seeks More Data on VT-1953

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$319.71K
Net Income
-$10.26M
Diluted EPS
-$4.86
Op. Cash Flow
-$3.75M
Gross Profit
$218.77K
Operating Income
-$10.45M
Cash & Equivalents
$4.98M
Debt / Equity
0.00×
Net Margin
-32.10×
Shares Outstanding
5.92M sh
Source: 10-K · filed 2026-03-18 · accession 0001213900-26-029500

Short Interest & Short Volume

1.58 days to cover

FINRA reported short interest of 18,468 shares in HIND as of the October 30, 2026 settlement, a 10.7% decrease from the prior period — about 1.6 days to cover at its recent average daily volume. On November 20, 2026, 28.7% of HIND volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)18,468 shares as of October 30, 2026
Change vs prior period▼ 10.7%
Days to cover1.58 at avg daily volume of 11,719
Daily short volume (FINRA facilities)28.7% of 25,499 shares on November 20, 2026
5-day average short volume18.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with H →
$1.2
52-week range · as of 2026-11-12 $1.2 – $5.88
Market cap
$8.42M
Volume
35K (2.9× avg)
3-mo avg 12.2K
Live data · 2026-11-21 21:03 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HIND - Latest Insights

HIND
Nov 12, 2026, 6:33 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $1.20 info
Change: -$0.430 (-26%) info
Market Cap: $8.422M info
HIND
Nov 12, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.63
Real-time Price: $1.20 info
Change: -$0.430 (-26%) info
Market Cap: $8.422M info
HIND
Oct 05, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $1.90
Real-time Price: $1.20 info
Change: -$0.700 (-37%) info
Market Cap: $8.422M info
HIND
Aug 25, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.25
Real-time Price: $1.20 info
Change: -$1.05 (-47%) info
Market Cap: $8.422M info
HIND
Aug 12, 2026, 4:32 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.22
Real-time Price: $1.20 info
Change: -$1.02 (-46%) info
Market Cap: $8.422M info
HIND
May 29, 2026, 8:42 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.30
Real-time Price: $1.20 info
Change: -$1.10 (-48%) info
Market Cap: $8.422M info
HIND
May 28, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.08
Real-time Price: $1.20 info
Change: -$0.8816 (-42%) info
Market Cap: $8.422M info
HIND
May 12, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.98
Real-time Price: $1.20 info
Change: -$0.780 (-39%) info
Market Cap: $8.422M info
HIND
May 12, 2026, 9:07 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $2.05
Real-time Price: $1.20 info
Change: -$0.8489 (-41%) info
Market Cap: $8.422M info
HIND
Apr 29, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.04
Real-time Price: $1.20 info
Change: -$0.840 (-41%) info
Market Cap: $8.422M info
HIND
Mar 20, 2026, 4:56 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $2.28
Real-time Price: $1.20 info
Change: -$1.08 (-47%) info
Market Cap: $8.422M info
HIND
Mar 18, 2026, 6:38 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $2.20
Real-time Price: $1.20 info
Change: -$1.00 (-45%) info
Market Cap: $8.422M info
HIND
Feb 25, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.46
Real-time Price: $1.20 info
Change: -$2.26 (-65%) info
Market Cap: $8.422M info
HIND
Feb 12, 2026, 9:16 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.61
Real-time Price: $1.20 info
Change: -$1.41 (-54%) info
Market Cap: $8.422M info
HIND
Jan 28, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.68
Real-time Price: $1.20 info
Change: -$1.48 (-55%) info
Market Cap: $8.422M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets